A Claims Analysis Comparing Citalopram with Sertraline as Initial Pharmacotherapy for a New Episode of Depression: Impact on Depression-Related Treatment Charges

Clinical Therapeutics

Volumn 26, Issue 1, 2004, Pages 115-124

  McLaughlin, Trent P ^a   Eaddy, Michael T ^b   Grudzinski, Amy N ^c  

^a Wolters Kluwer   (United States)

^b XCENDA   (United States)

^c PFIZER INC   (United States)

Author keywords

Citalopram; Cost of illness; Depression; Economics; Retrospective studies; Sertraline

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ACUTE DISEASE; ADULT; AGED; ANAMNESIS; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; COMMERCIAL PHENOMENA; CONTROLLED STUDY; COST CONTROL; DEPRESSION; DRUG USE; DYSTHYMIA; FEMALE; HEALTH CARE COST; HOSPITAL CHARGE; HUMAN; INFORMATION PROCESSING; INSURANCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANAGED CARE ORGANIZATION; MEDICAL SPECIALIST; MENTAL DISEASE; MULTIVARIATE ANALYSIS; OUTPATIENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SELECTION; POPULATION; PRESCRIPTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES;

EID: 1242294536     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90012-4     Document Type: Article

References (28)

1. American Psychiatric Association. Practice guideline for the treatment of patients with major depression. Working Group on Major Depressive Disorder. Available at: http://www.psych.org/psych_pract/treatg/pg/Depression2e. book.cfm. Accessed June 2003.
2. Croghan TW, Obenchain RL, Crown WE. What does treatment of depression really cost? Health Aff (Millwood). 1998;17:198-208.
3. Franco K, Tamburino M, Campbell N, et al. The added costs of depression to medical care. PharmacoEconomics. 1995;7:284-291.
4. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Depression: A neglected major illness. J Clin Psychiatry. 1993;54:419-424.
5. Agency for Health Care Policy and Research. Depression in Primary Care: Detection, Diagnosis, and Treatment. Rockville, Md: Agency for Health Care Policy and Research; 1993.
6. Young AS, Klap R, Sherboume CD, Wells KB. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry. 2001;58:55-61.
7. Brugha TS, Bebbington PE. The undertreatment of depression. Eur Arch Psychiatry Clin Neurosci. 1992; 242:103-108.
8. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157 (Suppl):1-45.
9. Russell JM, Berndt ER, Miceli R, et al. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manag Care. 1999;5: 597-606.
10. Noble S, Benfield P. Citalopram: A review of its pharmacology, clinical efficacy and tolerabuity in the treatment of depression. CNS Drugs. 1997;8:410-431.
11. Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol. 1997;12: 323-331.
12. Drug Topics Red Book, 2000. Montvale, NJ: Medical Economics Company; 2000.
13. Sclar DA, Skaer TL, Robison LM, Galin RS. Economic appraisal of citalopram in the management of single-episode depression. J Clin Psychopharmacol. 1999;19 (Suppl 1):47S-54S.
14. Symmetry Health Data Systems, Inc. Episode Treatment Groups User's Guide, Release 4.3. Phoenix, Ariz: Symmetry Health Data Systems; 2002.
15. Stempel DA, McLaughlin TP, Griffis DL, Stanford RH. Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: A 1-year follow-up. Respir Med. 2001;95:992-998.
16. Yazdani C, McLaughlin T, Smeeding JE, Walt J. Prevalence of treated dry eye disease in a managed care population. Clin Ther. 2001;23:1672-1682.
17. Lee J, Cummins G, Okamoto L. A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: A retrospective data-base analysis. Am J Manag Care. 2001;7(Suppl):S103-S112.
18. Health Insurance Portability and Accountability Act of 1996, 42 USC S300gg.
19. International Classification of Diseases, Ninth Revision, Clinical Modification. 5th ed. Salt Lake City, Utah: Medicode; 1997.
20. Pindyck RS, Rubinfeld DL. Econometric Models and Economic Forecasts. 4th ed. Boston, Mass: Irwin/ McGraw-Hill; 1998.
21. Berndt ER, Russell JM, Miceli R, et al. Comparing SSRI treatment costs for depression using retrospective claims data: The role of nonrandom selection and skewed data. Val Health. 2000;3:208-221.
22. Hylan TR, Kotsanos JG, Andersen JS, et al. Comparison of a decision analytic model with results from a naturalist economic clinical trial: An application to evaluating alternative antidepressants. Am J Manag Care. 1996;2:1211-1223.
23. United States Department of Defense Pharmacoeconomic Center. Department of Defense Pharmacoeconomic Center Update. January 2001, Volume 01, Issue 2.
24. Agency for Health Care Policy and Research. Depression in Primary Care, Volume 2: Treatment of Major Depression. Clinical Practice Guideline No. 5. Rockville, Md: Agency for Health Care Policy and Research; 1993. Publication 93-0551.
25. Johnson RE, McFarland BH, Nichols GA. Changing patterns of antidepressant use and costs in a health maintenance organisation. PharmacoEconomics. 1997; 11:274-286.
26. Venturini F, Sung JC, Nichol MB, Sellner JC. Utilization patterns of antidepressant medications in a patient population served by a primary care medical group. J Manag Care Pharm. 1999;5:243-249.
27. Navarro R, Valler WE, Spangler M. Antidepressant utilization in managed care: An evaluation of SSRI use in two HMO settings. Med Interface. 1995;8:114-123.
28. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: A study of anti-depressant use patterns in a Medicaid population. J Clin Psychiatry. 1990;51(Suppl):60-69.